A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
By Genmin Lu, F. Deguzman, S. Hollenbach, M. Karbarz, K. Abe, Gail Lee, P. Luan, A. Hutchaleelaha, M. Inagaki, P. Conley and 2 more. Nature Medicine, 2013
720 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/b32bd2d687c92fc52ca6912a4027dfc44e36c14b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Donat R. Spahn
- R. Rossaint
- B. Bouillon
- V. Černý
- J. Duranteau
- Gregory Y. H. Lip
- A. Banerjee
- B. Hunt
Citations in the corpus
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, background): “Specific antidotes against Xa antagonists are in development, including andexanet 17 alfa, a specific factor Xa inhibitor-reversing agent [629], however, these are not yet approved 18 for clinical use [630, 631].”
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Ex vivo, animal studies and phase 2 healthy volunteer studies demonstrate that andexanet reverses inhibition of factor Xa, corrects clotting times, restores hemostasis and reduces blood loss [174, 428–433]”
- Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “The first is a recombinant protein, named PRT064445 (also known as andexanet alfa or andexanet), which that serves as a universal antidote for factor Xa inhibitors, LMWH, and pentasaccharide.(161,162) A recent multicenter, prospective, open-label, single-group study evaluated 67 patients who had an ”
- Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report (2012, background): “Andexanet retains the ability to bind to NOACs with high affinity and a 1:1 stoichiometric ratio and by sequestering factor Xa inhibitors within the vascular space, endogenous factor Xa activity is restored.(229) Due to its pharmacodynamic half-life of 1 h, andexanet is administered as a bolus follo”